HTG Molecular Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

TUCSON, Ariz., Nov. 02, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016 in New York City.

HTG management is scheduled to present at 11:00 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the "Investors" section of HTG's website at: The webcast will be available on HTG's website for 90 days following the completion of the presentation.

About HTG:

Headquartered in Tucson, Arizona, HTG's mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at

Contact:Westwicke PartnersJamar IsmailPhone: 415-513-1282Email: jamar.ismail@westwicke.comTJ JohnsonPresident / CEOHTG Molecular DiagnosticsPhone: 520-547-2827 x130Email:

Primary Logo

If you liked this article you might like

The Bears Continue to Be Frustrated

Health Care Vote Impacts Trump's Deal Maker Image